Live Breaking News & Updates on Upadacitinib Ulcerative Colitis Program

Stay updated with breaking news from Upadacitinib ulcerative colitis program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
- 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p 0.001)[1]
- All ranked secondary endpoints were met[1]
- These results reaffirm findings from the first Phase 3 induction study, U-ACHIEVE[1,2]
- Safety results were consistent with the previous Phase 3 induction study and the known profile of upadacitinib, with no new safety risks observed[1-6]
- Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is being studied as an oral therapy for moderate to severe ulcerative colitis and several other immune-mediated diseases[1,7-14] ....

United States , Upadacitinib Monotherapy , Access Economics Pty , European Academy Of Dermatology , Abbvie Inc , Venerology Congress , Clinical Program , Upadacitinib Ulcerative Colitis Program , Drug Administration , European Commission , Exchange Commission , Crohn Colitis Foundation Of America , Adapted Mayo Score , Adapted Mayo , Upadacitinib Ulcerative Colitis , Safety Information , Important Safety , Mississippi River , Full Prescribing Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Rheumatoid Arthritis , Multicenter Phase , Patients With Active Ankylosing , Moderate To Severe Atopic Dermatitis ,

Second Phase 3 Induction Study Confirms Upadacitinib ) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

Second Phase 3 Induction Study Confirms Upadacitinib ) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

United States , Silvio Danese , Upadacitinib Monotherapy , Tom Hudson , Access Economics Pty , European Academy Of Dermatology , Abbvie Inc , Venerology Congress , Clinical Program , Upadacitinib Ulcerative Colitis Program , Drug Administration , European Commission , Exchange Commission , Crohn Colitis Foundation Of America , Adapted Mayo Score , Inflammatory Bowel Diseases Centre , Humanitas Research Hospital , Adapted Mayo , Safety Information , Important Safety Information , Mississippi River , Full Prescribing Information , Medication Guide , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports ,